Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

STERIS plc (STE) SEC Filings & Earnings Calls

EquiReason read 12 STERIS plc SEC filings in the last 12 months. Latest: 8-K on 2026-10-13 — STERIS plc subsidiary to acquire Xodus Medical for $2.1B cash plus up to $150M earnout, financed with debt; expected close by Dec 31, 2026..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

STESTERIS plcFollow STE — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
22.6B
P/E TTM
28.4
Dividend yield
1.1%
52-week
—
Next earnings
5 Nov, in 12 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

13 Oct 20268-K · 1.01STERIS plc subsidiary to acquire Xodus Medical for $2.1B cash plus up to $150M earnout, financed with debt; expected close by Dec 31, 2026.acquisitionopen

Risks flagged

Acquisition financed primarily with debt, increasing leverage; integration and regulatory approval risks.

“Acquisition expected to be financed primarily with debt; subject to regulatory approvals and customary closing conditions.”
Read the original on SEC EDGAR ↗
7 Aug 202610-QSTERIS reported Q1 FY2027 revenue growth of 7.3% and gross margin expansion of 70 bps, with operating income up 16.2%.earningsopen

Figures in the filing · each found in the filing text

Total revenues · Q1-2027$1.49B+7% y/y
Gross profit percentage · Q1-202745.8%
Product gross profit percentage · Product · Q1-202750.0%
Service gross profit percentage · Service · Q1-202741.7%
Income from operations · Q1-2027$286M+16% y/y
Net cash provided by operating activities · Q1-2027$367M-13% y/y
Free cash flow · Q1-2027$280M-14% y/y
Healthcare segment revenues · Healthcare · Q1-2027$1.05B+8% y/y
AST segment revenues · AST · Q1-2027$298M+6% y/y
Life Sciences segment revenues · Life Sciences · Q1-2027$147M+9% y/y

Risks flagged

Inflation pressure on margins

“unfavorable impacts from inflation (60 basis points)” · word for word

Restructuring execution risk

“The Company currently expects to incur total pre-tax restructuring charges of approximately $55 million to $70 million” · word for word

Free cash flow decline

“Free cash flow was $279.6 million in the first three months of fiscal 2027 compared to $326.5 million in the first three months of fiscal 2026” · word for word
Read the original on SEC EDGAR ↗
5 Aug 20268-K · 2.02, 2.05Revenue $1.50B (+7% y/y); Adjusted EPS $2.59 (+11% y/y); Healthcare revenue $1.05B (+8% y/y); Guidance: Revenue growth 7-8% reported, 6-7% constant currency organic; adjusted EPS $11.10-$11.30earningsopen

Figures in the filing · each found in the filing text

Revenue · Q1-2027$1.50B+7% y/y
Adjusted EPS · Q1-2027$2.59+11% y/y
Healthcare revenue · Healthcare · Q1-2027$1.05B+8% y/y
AST revenue · Applied Sterilization Technologies · Q1-2027$298M+6% y/y
Life Sciences revenue · Life Sciences · Q1-2027$147M+9% y/y
Free cash flow · Q1-2027$280M-14% y/y
Net cash provided by operations · Q1-2027$367M-13% y/y

Guidance

Revenue growth 7-8% reported, 6-7% constant currency organic; adjusted EPS $11.10-$11.30

Guidance reaffirmed with stable demand and margin outlook; capex increased for new facility investment

Risks flagged

Tariff cost pressure and inflation partially offset margin improvements

“increased tariff costs... inflation”

Restructuring plan with $55M-$70M charges over multiple years

“total pre-tax restructuring charges of approximately $55 million to $70 million” · word for word
Read the original on SEC EDGAR ↗
11 Jun 2026DEF 14AProxy statement for 2026 annual meeting, detailing executive compensation, governance, and shareholder proposals.open

Figures in the filing · each found in the filing text

Revenue · FY2026$5.94B+9% y/y
Net Income · FY2026$782M+27% y/y
Adjusted Net Income · FY2026$1.00B+9% y/y
Operating Cash Flow · FY2026$1.34B+17% y/y
Free Cash Flow · FY2026$983M+25% y/y
Adjusted EBIT · FY2026$1.38B
Adjusted Free Cash Flow · FY2026$1.01B
Dividend per Share · FY2026$0.63
Read the original on SEC EDGAR ↗
29 May 202610-KTotal revenues $5.94B (+9% y/y); Service revenues $2.88B (+11% y/y); Consumable revenues $1.81B (+7% y/y)open

Figures in the filing · each found in the filing text

Total revenues · FY2026$5.94B+9% y/y
Service revenues · Service · FY2026$2.88B+11% y/y
Consumable revenues · Consumable · FY2026$1.81B+7% y/y
Capital equipment revenues · Capital equipment · FY2026$1.25B+6% y/y
Gross profit percentage · FY202644.2%
Product gross profit percentage · Product · FY202646.9%
Service gross profit percentage · Service · FY202641.4%
United States revenues · United States · FY2026$4.33B+8% y/y
Other foreign revenues · Other foreign · FY2026$1.49B+11% y/y
Ireland revenues · Ireland · FY2026$109M+1% y/y

Risks flagged

Tariff cost pressure

“unfavorable impacts from tariffs (80 basis points)” · word for word

Inflation cost pressure

“inflation (70 basis points)” · word for word

Debt level

“As of March 31, 2026, STERIS had approximately $1,931.7 million of indebtedness outstanding” · word for word
Read the original on SEC EDGAR ↗
11 May 20268-K · 2.02Revenue from continuing operations $5.90B (+9% y/y); Adjusted net income per diluted share $10.17 (+10% y/y); Free cash flow $983M (+25% y/y); Guidance: FY2027 adjusted EPS $11.10-11.30 (+9-11%)earningsopen

Figures in the filing · each found in the filing text

Revenue from continuing operations · FY2026$5.90B+9% y/y
Adjusted net income per diluted share · FY2026$10.17+10% y/y
Free cash flow · FY2026$983M+25% y/y
Net cash provided by operations · FY2026$1.34B+17% y/y
Healthcare revenue · Healthcare · Q4-2026$1.14B+7% y/y
AST revenue · Applied Sterilization Technologies · Q4-2026$289M+6% y/y
Life Sciences revenue · Life Sciences · Q4-2026$163M+9% y/y

Guidance

FY2027 adjusted EPS $11.10-11.30 (+9-11%)

FY2027 guidance implies continued growth with revenue +7-8% and adjusted EPS +9-11%.

Risks flagged

Tariffs and inflation partially offset price/volume gains.

“The increase in operating income was primarily due to improved volume and price, which were significantly offset by tariffs and inflation.” · word for word
Read the original on SEC EDGAR ↗
7 May 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)SEC ↗
6 Apr 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)SEC ↗
6 Feb 202610-QSTERIS reported strong Q3 FY2026 results with revenue growth of 9.2% and operating income growth of 11.4%, though gross margin was pressured by tariffs and inflation.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2026$1.50B+9% y/y
Revenue · 9M-2026$4.35B+9% y/y
Gross Profit Percentage · Q3-202643.8%
Gross Profit Percentage · 9M-202644.4%
Income from Operations · Q3-2026$273M+11% y/y
Income from Operations · 9M-2026$785M+21% y/y
Free Cash Flow · 9M-2026$738M+25% y/y
Net Cash Provided by Operating Activities · 9M-2026$1.01B+13% y/y
Healthcare Backlog · Healthcare · Q3-2026$429M-1% y/y
Life Sciences Backlog · Life Sciences · Q3-2026$113M+33% y/y

Risks flagged

Tariff Cost Pressure

“Favorable impacts from pricing (110 basis points), productivity (40 basis points) and other cost reductions (30 basis points) were more than offset by unfavorable impacts from tariff costs (120 basis points), inflation (60 basis points), mix (60 basis points) and currency (10 basis points).” · word for word

Inflation Cost Pressure

“Favorable impacts from pricing (110 basis points), productivity (40 basis points) and other cost reductions (30 basis points) were more than offset by unfavorable impacts from tariff costs (120 basis points), inflation (60 basis points), mix (60 basis points) and currency (10 basis points).” · word for word
Read the original on SEC EDGAR ↗
4 Feb 20268-K · 2.02Total revenue from continuing operations $1.50B (+9% y/y); Constant currency organic revenue growth 8; Adjusted EPS from continuing operations $2.53 (+9% y/y); Guidance: Revenue growth 8-9%; constant currency organic revenue growth 7-8%; adearningsopen

Figures in the filing · each found in the filing text

Total revenue from continuing operations · Q3-2026$1.50B+9% y/y
Constant currency organic revenue growth · Q3-20268.0%
Adjusted EPS from continuing operations · Q3-2026$2.53+9% y/y
Net income from continuing operations · Q3-2026$193M+11% y/y
Free cash flow · 9M-2026$738M+25% y/y
Healthcare revenue · Healthcare · Q3-2026$1.10B+9% y/y
AST revenue · Applied Sterilization Technologies · Q3-2026$287M+11% y/y
Life Sciences revenue · Life Sciences · Q3-2026$146M+7% y/y
Capital expenditures guidance · FY2026$375M
Free cash flow guidance · FY2026$850M

Guidance

Revenue growth 8-9%; constant currency organic revenue growth 7-8%; adjusted EPS $10.15-$10.30

Fiscal 2026 outlook maintained with revenue growth 8-9%, constant currency organic growth 7-8%, and adjusted EPS $10.15-$10.30. Tariff headwinds increased to ~$55M but offset by strong execution and cost discipline.

Risks flagged

Tariff headwinds increased to ~$55M pre-tax profit impact, up from prior estimate of ~$45M, partially offsetting operational improvements.

“Included in this outlook is the negative impact of tariffs, estimated to reduce pre-tax profit by approximately $55 million, an increase from prior expectations of approximately $45 million.” · word for word

Inflation and labor/energy cost pressures persist across segments, partially offsetting volume and price gains.

“Operating income increases partially offset by tariff costs, inflation, labor and energy costs, and unfavorable mix.”
Read the original on SEC EDGAR ↗
6 Nov 202510-QSTERIS reported strong Q2 FY2026 results with revenue up 9.9% YoY, operating income up 21.0% YoY, and free cash flow up 53.2% YoY.earningsopen

Figures in the filing · each found in the filing text

Total revenues · Q2-2026$1.46B+10% y/y
Net income · H1-2026$412M
Free cash flow · H1-2026$528M+53% y/y
Operating cash flow · H1-2026$708M+28% y/y
Healthcare segment revenue · Healthcare · Q2-2026$1.03B+10% y/y
AST segment revenue · AST · Q2-2026$282M+10% y/y
Life Sciences segment revenue · Life Sciences · Q2-2026$145M+13% y/y
Healthcare segment backlog · Healthcare · 2025-09-30$428M+6% y/y
Life Sciences segment backlog · Life Sciences · 2025-09-30$114M+50% y/y
Debt-to-total capital ratio · 2025-09-3021.3%

Risks flagged

Tariff cost pressure

“unfavorable impacts from ... tariff costs (90 basis points)”

Inflation cost pressure

“unfavorable impacts from inflation (100 basis points)” · word for word

Restructuring execution risk

“Restructuring expenses $2.2 million for the three months ended September 30, 2025.”
Read the original on SEC EDGAR ↗
5 Nov 20258-K · 2.02Revenue $1.50B (+10% y/y); Adjusted EPS $2.47; Free cash flow $528M; Guidance: FY26 organic revenue growth 7-8% (prior 6-7%); adjusted EPS $10.15-$10.30 (prior $9.90-$10.15); FCF ~$850M (prior $820M)earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$1.50B+10% y/y
Adjusted EPS · Q2-2026$2.47
Free cash flow · H1-2026$528M
Healthcare revenue · Healthcare · Q2-2026$1.03B+9% y/y
AST revenue · Applied Sterilization Technologies · Q2-2026$282M+10% y/y
Life Sciences revenue · Life Sciences · Q2-2026$145M+13% y/y

Guidance

FY26 organic revenue growth 7-8% (prior 6-7%); adjusted EPS $10.15-$10.30 (prior $9.90-$10.15); FCF ~$850M (prior $820M)

Raised FY26 guidance across revenue, EPS, and free cash flow; strong execution.

Risks flagged

Tariff cost headwind of ~$45M pre-tax; partially offset by productivity and pricing.

“Negative impact of tariffs, estimated to reduce pre-tax profit by approximately $45 million.” · word for word
Read the original on SEC EDGAR ↗

STERIS plc — questions

What did STERIS plc file recently?
12 SEC filings in the last 12 months. Latest: 8-K on 2026-10-13 — STERIS plc subsidiary to acquire Xodus Medical for $2.1B cash plus up to $150M earnout, financed with debt; expected close by Dec 31, 2026.

Every figure on this page comes from STERIS plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.